As U.S. News tweaks methodology, top four cancer hospitals remain unchanged from last year (1) MD Anderson, (2) MSK, (3) Mayo, (4) DFCI

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

A blood test could map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy, according to researchers at Mayo Clinic and Stanford Medicine. The test they developed could help guide treatment decisions across multiple cancer types and treatments.

May 08, 2026

Vol.52 No.18

In Brief

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

The University of Texas MD Anderson Cancer Center announced a $10 million gift from Peggy and Carl Sewell to establish the Center for Cellular Language Intelligence, a research center created to understand the behavior of cancer cells at a high resolution, potentially enabling earlier cancer detection, smarter prevention, and more precise, personalized treatments.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

A Mayo Clinic has developed an artificial intelligence model that can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible.

May 01, 2026

Vol.52 No.17

In Brief

UT Austin announces first tech-native academic medical center in the U.S.

The University of Texas at Austin is building an integrated academic medical center from the ground up, where care, research, and education operate as one system organized around the patient. This model connects prevention, diagnosis, treatment, and long-term health into a continuous experience, particularly for those with complex and serious conditions.

April 24, 2026

Vol.52 No.16

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

As U.S. News tweaks methodology, top four cancer hospitals remain unchanged from last year

(1) MD Anderson, (2) MSK, (3) Mayo, (4) DFCI

YOU MAY BE INTERESTED IN

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

UT Austin announces first tech-native academic medical center in the U.S.

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Renew today!

Subscriber content

Never miss an issue!

Login

As U.S. News tweaks methodology, top four cancer hospitals remain unchanged from last year

(1) MD Anderson, (2) MSK, (3) Mayo, (4) DFCI

YOU MAY BE INTERESTED IN

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

UT Austin announces first tech-native academic medical center in the U.S.

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”